ERAS
Erasca Inc
NASDAQ: ERAS · HEALTHCARE · BIOTECHNOLOGY
$9.11
-7.98% today
Updated 2026-04-29
Market cap
$6.68B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $24
Volume
6.9M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$18.10
+98.68%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy1 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-21.72M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-242.81M | $-125.04M | $-161.65M | $-124.55M | $-29.09M |
| EPS | — | — | — | — | $-0.44 |
| Free cash flow | $-119.81M | $-102.99M | $-131.98M | $-95.58M | $-21.72M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Erasca Inc trades at $9.11. Our Smart Value Score of 25/100 indicates the stock is weak.
Frequently asked questions
What is Erasca Inc's stock price?
Erasca Inc (ERAS) trades at $9.11.
Is Erasca Inc overvalued?
Smart Value Score 25/100 (Grade F, Strong Sell).
What is the price target of Erasca Inc (ERAS)?
The analyst target price is $18.10, representing +98.7% upside from the current price of $9.11.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-33.30%
Beta1.05
50D MA$15.74
200D MA$6.57
Shares out0.31B
Float0.22B
Short ratio—
Avg volume6.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—